Exhibit 99.1
 
ENDRA Life Sciences Reports Third Quarter 2020 Financial Results and Provides Business Update
 
Conference call begins at 4:30 p.m. Eastern time today
 
ANN ARBOR, MI / ACCESSWIRE / November 16, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended September 30, 2020 and provided a business update. Highlights of the third quarter of 2020 and recent weeks include:
 
Installed the first TAEUS system at Rocky Vista University College of Osteopathic Medicine (RVUCOM), one of three research partnerships for ENDRA. The data from the RVUCOM study, along with other announced and future studies, will bolster the clinical evidence base and support the clinical utility of the TAEUS system in patients with non-alcoholic fatty liver disease (NAFLD) and inflammation (NASH) to support current and future commercialization efforts.
Secured the first clinical evaluation reference site in Germany and advanced two more European sites to final legal review, which the Company expects to execute before the end of the year. The Company also continued efforts to build out its strategic salesforce with key hires in the U.K. and Germany, while also identifying leading candidates in other major European markets.
Showcased TAEUS technology at important clinical conferences and trade shows, including The Digital International Liver Congress (ILC), hosted by the European Association for the Study of the Liver (EASL), and The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). ENDRA’s participation in these conferences helped to expand its qualified sales pipeline to more than 4,000 global clinicians, highlighting its unique position where there are no other practical clinical tools currently available.
Increased its intellectual property portfolio to 76 assets, up from 64 at the end of 2019, including adding key platform patents in the United States, Europe and China to protect current and future clinical applications of the Company’s technology.
Received approximately $5 million from the early exercise of common stock warrants. These proceeds extend ENDRA’s cash runway through key business inflection points, including establishing evaluation reference sites and initial sales in Europe, as well as the potential receipt of FDA clearance to begin commercialization in the U.S.
Remained on track to execute key milestones of establishing additional clinical evaluation reference sites in Europe in the fourth quarter of 2020.
 
 
 
 
Commenting on the quarter and recent weeks, Francois Michelon, chairman and chief executive officer of ENDRA, said, "I’m pleased with our continued progress to keep the company on track during these challenging times, including advancing our key European commercialization initiatives, as well as installing the first TAEUS system at Rocky Vista. In addition, we continue to work with the U.S. Food and Drug Administration to respond to questions related to our 510(k) Premarket Notification submission, with expectations that TAEUS will receive clearance.”
 
Renaud Maloberti, chief commercial officer, added, "The global pandemic is not tempering the enthusiasm of clinicians for our TAEUS solution to the growing NAFLD/NASH challenge, which impacts more than 1 billion people globally. We continue to make meaningful progress toward our first TAEUS system sale.”
 
Financial Results for Quarter Ended September 30, 2020
Operating expenses increased to $3.3 million in the third quarter of 2020, up from $2.6 million in the same period in 2019. The increase was primarily due to expenses related to the development of the TAEUS product line, regulatory submissions, and costs associated with TAEUS pre-commercialization activities.
Net loss in the third quarter of 2020 was $3.3 million, or ($0.15) per share, compared with a net loss of $3.4 million, or ($0.46) per share, in the third quarter of 2019.
The Company had cash and cash equivalents of $3.8 million as of September 30, 2020, compared with $6.2 million as of December 31, 2019, with no long-term debt.
 
Conference Call and Webcast Access
Management will host a conference call and webcast today at 4:30 p.m. ET to discuss these results and provide an update on recent corporate developments.
 
Dial-in Number
U.S./Canada Dial-in Number: 844-369-8774
International Dial-in Number: 862-298-0844
 
Replay Dial-in Number: 877-481-4010
Replay International Dial-in Number: 919-882-2331
Replay Passcode: 38486

A telephone replay will be available from November 16, 2020 through 4:30 p.m. ET on November 23, 2020.
 
A live audio webcast will be available through the Events and Presentations page of the Investors section of the company's website at www.endrainc.com. A replay of the webcast will be available on the website for 90 days.
 
 
 
 
About ENDRA Life Sciences Inc.
 
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with the over one million ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.comSee more. Do more. Live better®.
 
Forward-Looking Statements
 
All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, estimates of the timing of future events and achievements, such as the expectations regarding commercializing the TAEUS device, establishing evaluation reference sites and initial sales in Europe, receipt of U.S. Food and Drug Administration regulatory approval, and expectations concerning ENDRA's business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; the impact of COVID-19 on our business plans; our ability to find and maintain development partners, market acceptance of our technology and the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this news release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
 
Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com
 
Investor Relations Contact:
Kim Sutton Golodetz
LHA Investor Relations
(212) 838-3777
kgolodetz@lhai.com
 
 
 
 
ENDRA Life Sciences Inc.
Condensed Consolidated Balance Sheets
 
 
 
September 30,
 
 
 December 31,
 
Assets
 
2020
 
 
2019
 
 Assets
 
 (unaudited)
 
 
 
 
Cash
 $3,793,292 
 $6,174,207 
Prepaid expenses
  561,554 
  116,749 
Inventory
  323,208 
  113,442 
Other current assets
  101,451 
  130,701 
Total Current Assets
  4,779,505 
  6,535,099 
Other Assets
    
    
Fixed assets, net
  225,620 
  236,251 
Right of use assets
  356,060 
  404,919 
Total Assets
 $5,361,185 
 $7,176,269 
 
    
    
Liabilities and Stockholders’ Equity
    
    
Current Liabilities
    
    
Accounts payable and accrued liabilities
 $1,325,005 
 $1,708,525 
Convertible notes payable, net of discount
  - 
  298,069 
Lease liabilities, current portion
  73,624 
  66,193 
Total Current Liabilities
  1,398,629 
  2,072,787 
 
    
    
Long Term Debt
    
    
Loans
  337,084 
  - 
Lease liabilities
  290,489 
  342,812 
Total Long Term Debt
  627,573 
  342,812 
 
    
    
Total Liabilities
  2,026,202 
  2,415,599 
 
    
    
Stockholders’ Equity
    
    
Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 190 and 6,338 shares issued and outstanding, respectively
  1 
  1 
Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; no shares and 352 shares issued and outstanding, respectively
  - 
  - 
Common stock, $0.0001 par value; 80,000,000 shares authorized; 25,015,710 and 8,421,401 shares issued and outstanding, respectively
  2,500 
  842 
Additional paid in capital
  58,281,673 
  49,933,736 
Stock payable
  224,163 
  43,528 
Stock receivable
  (85,626)
  - 
Accumulated deficit
  (55,087,728)
  (45,217,437)
Total Stockholders’ Equity
  3,334,983 
  4,760,670 
Total Liabilities and Stockholders’ Equity
 $5,361,185 
 $7,176,269 
 
 
 
 
 
ENDRA Life Sciences Inc.
Condensed Consolidated Statements of Operations
 (Unaudited)
 
 
 
Three Months Ended
 
 
Three Months Ended
 
 
Nine Months Ended
 
 
Nine Months Ended
 
 
 
September 30,
 
 
September 30,
 
 
September 30,
 
 
September 30,
 
 
 
2020
 
 
2019
 
 
2020
 
 
2019
 
Operating Expenses
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 $1,769,339 
 $1,468,441 
 $4,774,534 
 $4,546,746 
Sales and marketing
  139,751 
  100,203 
  389,469 
  245,364 
General and administrative
  1,346,360 
  1,071,889 
  4,083,572 
  2,920,815 
Total operating expenses
  3,255,450 
  2,640,533 
  9,247,575 
  7,712,925 
 
    
    
    
    
Operating loss
  (3,255,450)
  (2,640,533)
  (9,247,575)
  (7,712,925)
 
    
    
    
    
Other Expenses
    
    
    
    
Amortization of debt discount
  - 
  (728,417)
  (232,426)
  (728,417)
Other income (expense)
  (2,621)
  (44,612)
  5,261 
  (55,328)
Total other expenses
  (2,621)
  (773,029)
  (227,165)
  (783,745)
 
    
    
    
    
Loss from operations before income taxes
  (3,258,071)
  (3,413,562)
  (9,474,740)
  (8,496,670)
 
    
    
    
    
Provision for income taxes
  - 
  - 
  - 
  - 
 
    
    
    
    
Net Loss
 $(3,258,071)
 $(3,413,562)
 $(9,474,740)
 $(8,496,670)
 
    
    
    
    
Deemed dividend
  (395,551)
  - 
  (395,551)
  - 
 
    
    
    
    
Net Loss attributable to common stockholders
 $(3,653,622)
 $(3,413,562)
 $(9,870,291)
 $(8,496,670)
 
    
    
    
    
Net loss per share – basic and diluted
 $(0.15)
 $(0.46)
 $(0.41)
 $(1.14)
 
    
    
    
    
Weighted average common shares – basic and diluted
  23,889,591 
  7,428,788 
  23,808,012 
  7,424,713 
 
 
 
 
 
ENDRA Life Sciences Inc.
Condensed Consolidated Statements of Cash Flows
 (Unaudited) 
 
 
 
Nine Months Ended
 
 
Nine Months Ended
 
 
 
September 30,
 
 
September 30,
 
 
 
2020
 
 
2019
 
Cash Flows from Operating Activities
 
 
 
 
 
 
Net loss
 $(9,474,740)
 $(8,496,670)
Adjustments to reconcile net loss to net cash used in operating activities:
    
    
Depreciation and amortization
  45,114 
  59,673 
Common stock, options and warrants issued for services
  1,559,232 
  1,020,300 
Amortization of debt discount
  232,426 
  728,417 
Amortization of right of use assets
  48,859 
  - 
Stock payable for investor relations
  30,000 
  - 
Changes in operating assets and liabilities:
    
    
Increase in prepaid expenses
  (444,805)
  (61,234)
Decrease in lease liability
  (44,892)
  - 
Increase in inventory
  (209,766)
  (68,387)
Decrease (increase) in other asset
  29,250 
  (93,075)
(Decrease) increase in accounts payable and accrued liabilities
  (444,167)
  229,640 
Net cash used in operating activities
  (8,673,489)
  (6,681,336)
 
    
    
Cash Flows from Investing Activities
    
    
Purchases of fixed assets
  (10,483)
  (5,238)
Net cash used in investing activities
  (10,483)
  (5,238)
 
    
    
Cash Flows from Financing Activities
    
    
Proceeds from senior secured convertible promissory notes, net of fees
  - 
  2,490,501 
Proceeds from warrant exercise
  4,644,084 
  - 
Proceeds from loans
  337,084 
  - 
Proceeds from issuance of common stock
  1,321,890 
  - 
Net cash provided by financing activities
  6,303,058 
  2,490,501 
 
    
    
Net decrease in cash
  (2,380,914)
  (4,196,073)
 
    
    
Cash, beginning of period
  6,174,207 
  6,471,375 
 
    
    
Cash, end of period
 $3,793,293 
 $2,275,302 
 
    
    
Supplemental disclosures of cash items
    
    
Interest paid
 $1,920 
 $- 
Income tax paid
 $- 
 $- 
 
    
    
Supplemental disclosures of non-cash items
    
    
Discount on convertible notes
 $- 
 $2,490,501 
Conversion of convertible notes and accrued interest
 $493,814 
 $140,405 
Deemed dividend related to warrant repriced
 $395,551 
    
Conversion of Series A Convertible Preferred Stock
 $(717)
 $- 
Conversion of Series B Convertible Preferred Stock
 $(36)
 $- 
Stock dividend payable
 $(47,641)
 $- 
Right of use asset
 $356,060 
 $(420,488)
Lease liability
 $364,113 
 $424,210 
 
 

View differences made from one to another to evaluate Endra Life Sciences Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Endra Life Sciences Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account